|
시장보고서
상품코드
1890932
당뇨병성 신증 시장 : 약제 클래스별, 당뇨병 유형별, 투여 경로별, 성별, 연령층별, 질환 단계별, 유통경로별, 최종사용자별, 지역Diabetic Nephropathy Market, By Drug Class, By Diabetes Type, By Route of Administration, By Gender, By Age Group, By Disease Stage, By Distribution Channel, By End User, By Geography |
||||||
당뇨병성 신증 시장은 2025년에 35억 1,000만 달러로 추정되며, 2032년까지 53억 8,000만 달러에 달할 것으로 예측됩니다. 2025-2032년 CAGR 6.3%로 성장할 전망입니다.
| 리포트 내용 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2024년 | 2025년 시장 규모 : | 35억 1,000만 달러 |
| 과거 데이터 대상 기간 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간인 2025-2032년의 CAGR : | 6.30% | 2032년 예측 : | 53억 8,000만 달러 |
세계 당뇨병성 신증 시장은 당뇨병의 가장 심각한 합병증 중 하나를 다루는 광범위한 신장학 및 당뇨병 치료 생태계에서 중요한 부문입니다.
당뇨병성 신증(일명 당뇨병성 신질환)은 당뇨병 환자의 약 20-40%에게 영향을 미치며, 전 세계에서 말기 신장질환의 주요 원인으로 꼽히고 있습니다. 이 진행성 질환은 고혈당 상태에 장기간 노출되어 신장 기능이 점진적으로 악화되어 결국 만성 신장 질환으로 진행하며, 치료를 소홀히 하면 신부전증으로 이어질 수 있습니다.
이 시장은 안지오텐신 전환효소(ACE) 억제제, 안지오텐신 수용체 차단제(ARB), 이뇨제, 칼슘 채널 차단제, 그리고 당뇨병성 신질환의 진행에 관여하는 특정 경로를 표적으로 하는 새로운 혁신적 치료법까지 종합적인 치료 중재를 포괄하고 있습니다.
세계 당뇨병 유병률이 급격히 증가하여 전 세계 5억 3,700만 명 이상의 성인에게 영향을 미치고 있는 가운데, 당뇨병성 신증 시장은 제약사, 의료 서비스 프로바이더, 규제 당국으로부터 큰 관심을 받고 있습니다. 조기 발견에 대한 인식 증가, 진단 능력의 향상, 혁신적인 치료법 개발이 결합되어 시장의 견고한 성장 궤도를 지원하고 세계 투자 및 연구개발의 초점이 되고 있습니다.
시장 역학
세계 당뇨병성 신증 시장은 몇 가지 강력한 촉진요인에 의해 주도되고 있습니다. 가장 중요한 요인은 전 세계 당뇨병 유병률, 특히 2형 당뇨병의 급격한 증가이며, 이는 당뇨병성 신장 합병증 발생률 증가와 직접적인 관련이 있습니다. 세계 인구의 고령화, 좌식 생활, 비만율 증가는 당뇨병이 확산될 수 있는 완벽한 조건을 만들어 냈고, 그 결과 신장병 관리 솔루션에 대한 수요를 촉진하고 있습니다.
의료진과 환자들의 조기 개입과 정기적인 모니터링의 중요성에 대한 인식이 높아지면서 검진율 향상과 조기 진단으로 이어져 대상 환자층이 확대되고 있습니다. 바이오마커 식별 및 비침습적 모니터링 시스템을 포함한 진단 툴의 기술 발전은 질병 감지 능력을 향상시켰고, SGLT2 억제제 및 엔도셀린 수용체 길항제와 같은 새로운 치료 표적에 초점을 맞춘 의약품 혁신은 치료 패러다임에 혁명을 일으켰습니다.
그러나 시장에는 심각한 제약도 존재합니다. 첨단 치료 및 진단 절차의 높은 비용은 특히 당뇨병 부담이 가장 높은 개발도상국에서 접근성을 제한하고 있습니다. 의료 인프라 부족, 전문 신장 전문의 부족, 특정 시장의 불충분한 상환 정책도 시장 성장에 대한 추가적인 도전이 되고 있습니다. 장기적인 투약 계획에 대한 환자 순응도 문제와 초기 당뇨병성 신증의 무증상 특성으로 인해 치료 시작이 지연되는 경우가 많습니다.
이러한 과제가 있는 반면, 당뇨병 환자 수가 방대한 신흥 시장, 유전자 프로파일링에 기반한 맞춤형 의료 접근법 개발, 질병 관리에 인공지능의 통합, 여러 경로를 동시에 표적으로 삼는 병용요법의 가능성 등 큰 기회도 존재합니다. 예방의료와 가치 기반 헬스케어 모델에 대한 관심이 높아지는 것도 시장 확대의 새로운 길을 보여주고 있습니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 연평균 성장률(CAGR)을 나타내는 세계 당뇨병성 신증 시장에 대한 상세한 분석 정보를 제공합니다.
- 각 부문의 잠재적 매출기회를 확인하고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 이 보고서는 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서에서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 당뇨병성 신증 시장의 주요 기업 개요을 제공합니다.
- 이 보고서는 마케팅 담당자 및 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 세계 당뇨병성 신증 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 당뇨병성 신증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 범위
- 리포트 개요
- 시장 정의와 범위
- 개요
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porter의 산업 분석
- 합병·인수의 동향
- 업계 동향
제4장 세계의 당뇨병성 신증 시장 : 약제 클래스별, 2020-2032년
- 안지오텐신 전환 효소(ACE) 저해제
- 안지오텐신 II 수용체 길항제(ARB)
- Sodium Glucose Cotransporter 2(SGLT2) 저해제
- 미네랄로코르티코이드 수용체 길항제(MRA)
- 이뇨제
- 칼슘 채널 차단약
- 기타(예 : GLP-1 수용체 작용제, DPP-4저해제, 엔도셀린 A수용체 길항제, 섬유화/염증 조절약)
제5장 세계의 당뇨병성 신증 시장 : 당뇨병 유형별, 2020-2032년
- 1형 당뇨병
- 2형 당뇨병
제6장 세계의 당뇨병성 신증 시장 : 투여 경로별, 2020-2032년
- 경구
- 비경구(주사제/점적제)
- 기타 투여 경로(예 : 경피 흡수, 신규 전달법)
제7장 세계의 당뇨병성 신증 시장 : 성별, 2020-2032년
- 남성
- 여성
제8장 세계의 당뇨병성 신증 시장 : 연령층별, 2020-2032년
- 소아
- 성인
제9장 세계의 당뇨병성 신증 시장 : 질환 단계별, 2020-2032년
- 초기 단계
- 중기 단계
- 말기 신부전(ESRD)
제10장 세계의 당뇨병성 신증 시장 : 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제11장 세계의 당뇨병성 신증 시장 : 최종사용자별, 2020-2032년
- 병원 및 진료소
- 전문 신장병 센터
- 재택 의료/외래 의료
- 기타 시설(투석 센터, 신장 이식 유닛)
제12장 세계의 당뇨병성 신증 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제13장 경쟁 구도
- AstraZeneca plc
- Bayer AG
- Eli Lilly and Company
- Johnson &Johnson
- Novartis AG
- Sanofi S.A.
- Merck &Co., Inc.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- AbbVie Inc.
- Abbott Laboratories
- Takeda Pharmaceutical Company Limited
- Novo Nordisk A/S
- Amgen Inc.
제14장 애널리스트의 권장사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제15장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
- 출판사 소개
Diabetic Nephropathy Market is estimated to be valued at USD 3.51 Bn in 2025 and is expected to reach USD 5.38 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.3% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.51 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.30% | 2032 Value Projection: | USD 5.38 Bn |
The global diabetic nephropathy market represents a critical segment within the broader nephrology and diabetes care ecosystem, addressing one of the most severe complications of diabetes mellitus.
Diabetic nephropathy, also known as diabetic kidney disease, affects approximately 20-40% of patients with diabetes and stands as the leading cause of end-stage renal disease worldwide. This progressive condition involves the gradual deterioration of kidney function due to prolonged exposure to high blood glucose levels, ultimately leading to chronic kidney disease and potential kidney failure if left untreated.
The market encompasses a comprehensive range of therapeutic interventions including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), diuretics, calcium channel blockers, and emerging novel therapies targeting specific pathways involved in diabetic kidney disease progression.
With the global diabetes prevalence continuing to rise dramatically, affecting over 537 million adults worldwide, the diabetic nephropathy market has gained substantial attention from pharmaceutical companies, healthcare providers, and regulatory authorities. The increasing awareness about early detection, improved diagnostic capabilities, and the development of innovative treatment modalities have collectively contributed to the market's robust growth trajectory, making it a focal point for investment and research activities globally.
Market Dynamics
The global diabetic nephropathy market is propelled by several compelling drivers, with the most significant being the exponential rise in diabetes prevalence worldwide, particularly Type 2 diabetes, which directly correlates with increased incidence of diabetic kidney complications. The aging global population, sedentary lifestyles, and rising obesity rates have created a perfect storm for diabetes proliferation, subsequently driving demand for nephropathy management solutions.
Growing awareness among healthcare professionals and patients about the importance of early intervention and regular monitoring has led to increased screening rates and earlier diagnosis, expanding the addressable patient population. Technological advancements in diagnostic tools, including biomarker identification and non-invasive monitoring systems, have enhanced disease detection capabilities, while pharmaceutical innovations focusing on novel therapeutic targets such as SGLT2 inhibitors and endothelin receptor antagonists have revolutionized treatment paradigms.
However, the market faces significant restraints including the high cost of advanced therapeutic and diagnostic procedures, which limits accessibility particularly in developing regions where diabetes burden is highest. Limited healthcare infrastructure, shortage of specialized nephrologists, and inadequate reimbursement policies in certain markets pose additional challenges to market growth. Patient compliance issues with long-term medication regimens and the asymptomatic nature of early-stage diabetic nephropathy often result in delayed treatment initiation.
Despite these challenges, substantial opportunities exist in the form of emerging markets with large diabetic populations, development of personalized medicine approaches based on genetic profiling, integration of artificial intelligence in disease management, and the potential for combination therapies that target multiple pathways simultaneously. The increasing focus on preventive care and value-based healthcare models presents additional avenues for market expansion.
Key Features of the Study
- This report provides in-depth analysis of the global diabetic nephropathy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diabetic nephropathy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AstraZeneca plc, Bayer AG, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, AbbVie Inc., Abbott Laboratories, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, and Amgen Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global diabetic nephropathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic nephropathy market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Angiotensin II Receptor Blockers (ARBs)
- Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
- Mineralocorticoid Receptor Antagonists (MRAs)
- Diuretics
- Calcium Channel Blockers
- Others (e.g., GLP 1 Receptor Agonists, DPP 4 Inhibitors, Endothelin A Receptor Antagonists, Fibrosis/Inflammation Modulators)
- Diabetes Type Insights (Revenue, USD Bn, 2020 - 2032)
- Type 1 Diabetes
- Type 2 Diabetes
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral (injectables/infusions)
- Other routes (e.g., transdermal, novel delivery)
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Disease Stage Insights (Revenue, USD Bn, 2020 - 2032)
- Early Stage
- Moderate Stage
- End-Stage Renal Disease (ESRD)
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and Clinics
- Specialty Nephrology Centers
- Home Care/Ambulatory Care
- Other settings (dialysis centers, renal transplant units)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AstraZeneca plc
- Bayer AG
- Eli Lilly and Company
- Johnson & Johnson
- Novartis AG
- Sanofi S.A.
- Merck & Co., Inc.
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- AbbVie Inc.
- Abbott Laboratories
- Takeda Pharmaceutical Company Limited
- Novo Nordisk A/S
- Amgen Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Diabetic Nephropathy Market, By Drug Class
- Global Diabetic Nephropathy Market, By Diabetes Type
- Global Diabetic Nephropathy Market, By Route of Administration
- Global Diabetic Nephropathy Market, By Gender
- Global Diabetic Nephropathy Market, By Age Group
- Global Diabetic Nephropathy Market, By Disease Stage
- Global Diabetic Nephropathy Market, By Distribution Channel
- Global Diabetic Nephropathy Market, By End User
- Global Diabetic Nephropathy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Diabetic Nephropathy Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Angiotensin Converting Enzyme (ACE) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Angiotensin II Receptor Blockers (ARBs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Mineralocorticoid Receptor Antagonists (MRAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (e.g., GLP 1 Receptor Agonists, DPP 4 Inhibitors, Endothelin A Receptor Antagonists, Fibrosis/Inflammation Modulators)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Diabetic Nephropathy Market, By Diabetes Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Diabetic Nephropathy Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral (injectables/infusions)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other routes (e.g., transdermal, novel delivery)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Diabetic Nephropathy Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Diabetic Nephropathy Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Diabetic Nephropathy Market, By Disease Stage, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Early Stage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Moderate Stage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- End-Stage Renal Disease (ESRD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Diabetic Nephropathy Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Diabetic Nephropathy Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Nephrology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Home Care/Ambulatory Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other settings (dialysis centers, renal transplant units)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Diabetic Nephropathy Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Diabetes Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Stage, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User , 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Abbott Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
